Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
about
Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stressClinical Management of Priapism: A ReviewClinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an updateA pathophysiology-based approach to the management of early priapismMedical management of ischemic stuttering priapism: a contemporary review of the literatureMolecular pathophysiology of priapism: emerging targetsSystematic drug repositioning based on clinical side-effectsEstablishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism.Sustained nitric oxide (NO)-releasing compound reverses dysregulated NO signal transduction in priapism.Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease.Post-translational inactivation of endothelial nitric oxide synthase in the transgenic sickle cell mouse penisHow I manage priapism due to sickle cell disease.Management of priapism: an update for clinicians.Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directionsPharmacotherapy in sickle cell disease--state of the art and future prospectsSubacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 DysregulationTargeting NADPH oxidase decreases oxidative stress in the transgenic sickle cell mouse penisPDE5 inhibitors beyond erectile dysfunction.Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature.Advances in clinical research in sickle cell disease.Attenuated RhoA/Rho-kinase signaling in penis of transgenic sickle cell miceSickle cell disease at the dawn of the molecular era.Stuttering priapism: insights into pathogenesis and management.Case Report: Conversion of a Low-Flow to High-Flow Priapism.Nitrergic Mechanisms for Management of Recurrent PriapismHow I treat priapism.Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis.Priapism in sickle cell anemia: emerging mechanistic understanding and better preventative strategies.Erectile dysfunction after sickle cell disease-associated recurrent ischemic priapism: profile and risk factors.Contemporary best practice in the evaluation and management of stuttering priapism.Tadalafil in the treatment of erectile dysfunction.Prostate cancer risk after anti-androgen treatment for priapism.Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism.Clinical course linkage among different priapism subtypes: Dilemma in the management strategies.
P2860
Q21559608-20DAB56A-B0E3-4F81-99FA-F448776D29B6Q26750575-FAC07DC3-EF98-492A-B382-4999BAFF1F31Q26775925-0732428E-04C3-433E-AB73-6517B2B4DC7DQ26825268-BFCA6A23-F433-41B2-83BF-5038F46A5A2EQ26851728-70D2ECFF-E83F-4A1F-8D76-F22855D24805Q27010069-43C34DEC-FB90-4139-9799-FF6FC3E55A77Q28478506-3E61B3F4-AB11-41B9-868D-59F4C66CC47BQ33572814-BEC8E20B-CF9A-4F56-A157-AA100052B4A5Q33713601-91361903-289F-4BB4-AEBC-F8B70AAEE9D1Q33859035-18923288-635B-458D-9A8F-D328184447DEQ33873920-830DA396-9D15-4406-AAD5-440137D5FD12Q34321121-B40EBF30-01CB-46B1-B92D-4C5BE769A645Q34536704-495FE422-D8E8-435A-88C4-5D96E1F66205Q34579250-FDE6BAAB-D16D-4E15-A8FD-25DA656DA1F4Q34992760-DD45D490-50BD-4E87-8409-C98261771D1FQ35220342-C198A910-ACB6-4086-AFD0-CD07AC98798EQ36144285-D1701F6C-2C7C-4710-A106-9308EB5F1B8DQ36213625-2EB5714F-1CC8-4B1F-9BF7-3F15FCD48481Q36878017-ACA822C9-E384-45CF-99B6-F48CB917AC18Q37084173-09D7EAC8-EA0F-4DBB-A76A-EC7A206BC131Q37110303-8B341A64-F3D2-4888-9F25-44B9CB935AA3Q37146167-A0B00786-CEE7-47D3-8B17-27976289F9FAQ37650483-34FFF405-57D4-4869-9F98-83D4237B8D5AQ38014717-3C1C747D-4ABD-47A2-A617-CC44C188B7B3Q38344024-EA42D81E-F02B-4324-A7BA-06B012C605CEQ38610620-C2B19392-F2A8-4F22-BA18-0DC21AADDF44Q39025090-2F92249C-6A9D-42A3-A2BC-AADB1AFA54DBQ39290264-9F9518AE-57D9-487A-87E9-39BB601AF83FQ39760861-5DDF8995-7A38-40DC-B38E-B905567D87C7Q40852821-E72067A6-94DA-4DFA-82A0-1076553362EEQ41078738-52146590-DB38-4CB2-9DC8-D8B37F71EDC0Q41978073-AFF95069-9109-4A17-8F3E-FED566B463A1Q45017951-4448CA93-1F68-4BB1-9BE0-69576710A1D5Q47700617-D5A183AF-F70E-43DA-97D1-351F8AC76D15Q50778371-8E52A24D-BB22-4205-AF95-566F875640FF
P2860
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
@ast
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
@en
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
@nl
type
label
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
@ast
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
@en
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
@nl
prefLabel
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
@ast
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
@en
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
@nl
P2093
P1433
P1476
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
@en
P2093
Arthur L Burnett
Biljana Musicki
Hunter C Champion
Trinity J Bivalacqua
P304
P356
10.1016/J.UROLOGY.2005.11.045
P407
P577
2006-05-01T00:00:00Z